Ticker >

Vanta Bioscience share price

Vanta Bioscience Ltd.

BSE: 540729 SECTOR: Business Support  8686   8   0

63.00
+1.49 (2.42%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 63

Today's Low

₹ 59

52 Week High

₹ 101.64

52 Week Low

₹ 37

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

39.77 Cr.

Enterprise Value

65.46 Cr.

No. of Shares

0.63 Cr.

P/E

0

P/B

2.01

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  31.28

CASH

0.07 Cr.

DEBT

25.76 Cr.

Promoter Holding

69.36 %

EPS (TTM)

₹  -6.71

Sales Growth

-44.69%

ROE

-19.37 %

ROCE

-2.44%

Profit Growth

-5495.52 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-44.69%
3 Year-27.77%
5 Year5.93%

Profit Growth

1 Year-5495.52%
3 Year-263%
5 Year-374.27%

ROE%

1 Year-19.37%
3 Year-5.69%
5 Year-1.84%

ROCE %

1 Year-2.44%
3 Year3.19%
5 Year5.45%

Debt/Equity

1.3048

Price to Cash Flow

61.68

Interest Cover Ratio

-0.354233951565816

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 69.36 0
Sep 2023 69.36 0
Mar 2023 69.36 0
Sep 2022 69.36 0
Mar 2022 69 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -421.940320949306 days.
  • The company has a high promoter holding of 69.36%.

 Limitations

  • The company has shown a poor profit growth of -262.999956071472% for the Past 3 years.
  • The company has shown a poor revenue growth of -27.7727315993032% for the Past 3 years.
  • Company has a poor ROE of -5.68555645886272% over the past 3 years.
  • Company has a poor ROCE of 3.18914177889398% over the past 3 years
  • Company has low Interest coverage ratio of -0.354233951565816.
  • The company is trading at a high EV/EBITDA of 436.3844.

Quarterly Result (All Figures in Cr.)

Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 12.08 13.72 9.82 9.35 5.17
Total Expenditure 8.81 9.41 5.92 5.95 5.65
Operating Profit 3.27 4.32 3.89 3.4 -0.48
Other Income 0.23 0.11 0.02 0.17 0.63
Interest 1.69 1.95 2.06 2.11 3.11
Depreciation 0.71 1.19 1.25 1.32 1.25
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.1 1.29 0.61 0.14 -4.21
Tax 0.4 0.31 0.13 0.06 0.03
Net Profit 0.69 0.98 0.47 0.08 -4.24
Adjusted EPS (Rs.) 1.1 1.55 0.75 0.12 -6.71

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 6.31 6.31 6.31 6.31 6.31
Total Reserves 15.93 17.13 17.6 17.68 13.43
Borrowings 12.17 10.43 10.77 15.64 20.84
Other N/C liabilities 0.4 0.59 0.72 0.78 0.81
Current liabilities 3.3 7.29 10.9 10.03 10.25
Total Liabilities 38.12 41.74 46.3 50.44 51.64
Assets
Net Block 17.9 20.76 29.39 36.12 37.4
Capital WIP 3.7 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 2 3 3 3 3
Loans & Advances 0.35 0.35 0.35 0.27 0.11
Other N/C Assets 0 0 0 0 0
Current Assets 14.17 17.64 13.56 11.05 11.13
Total Assets 38.12 41.74 46.3 50.44 51.64
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 1.1 1.29 0.61 0.14 -4.21
Adjustment 2.4 3.14 3.29 3.43 4.36
Changes in Assets & Liabilities -3.56 -1.26 7.11 3.13 0.49
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.06 3.17 11.01 6.7 0.64
Investing Cash Flow -4.48 -1.35 -9.86 -8.05 -2.53
Financing Cash Flow 4.73 -2.02 -1.17 1.35 1.88
Net Cash Flow 0.2 -0.2 -0.02 0 0

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Sep 2022% Mar 2023% Sep 2023% Mar 2024%
promoters 69.00 69.36 69.36 69.36 69.36
dopesh raja mulakala 7.26 7.26 7.26 7.26 7.26
m sajan kiran 0.32 0.32 0.32 0.32 0.32
mohan krishna mulakala 55.22 55.22 55.22 55.22 55.22
mulakala karishma 0.79 0.79 0.79 0.79 0.79
pradeep chowdary veeramac... - 0.34 0.34 0.34 0.34
s chandra sekhar rao - 1.94 1.94 1.94 1.94
shravan chintapatla 1.27 1.27 1.27 1.27 1.27
soumya simhadri 1.43 1.43 1.43 1.43 1.43
vyasmurti madhavrao shing... 0.79 0.79 0.79 0.79 0.79
chandra shekar rao simhad... 1.58 - - - -
pradeep chowdary veeramac... 0.34 - - - -
PARTICULARS Mar 2022% Sep 2022% Mar 2023% Sep 2023% Mar 2024%
investors 31.00 30.64 30.64 30.64 30.64
bosco armando menezes - - - - 1.01
emily bosco menezes - - - - 1.02
m shikar - - - - 1.28
vimalchand a . - 1.11 - - 1.09
hridaan chopraa - 1.40 1.40 1.40 -
vimalchand a - - 1.09 1.09 -
s s seema 1.07 1.08 1.08 - -
hridaan chopra 1.40 - - - -
vimal chanda 1.14 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Vanta Bioscience Stock Price Analysis and Quick Research Report. Is Vanta Bioscience an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Vanta Bioscience . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Vanta Bioscience has a PE ratio of -9.38981130950607 which is low and comparatively undervalued .

  • Share Price: - The current share price of Vanta Bioscience is Rs 63. One can use valuation calculators of ticker to know if Vanta Bioscience share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Vanta Bioscience has ROA of -8.29811280809417 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Vanta Bioscience has a Current ratio of 1.08647682011384 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Vanta Bioscience has a ROE of -19.3708207541153 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Vanta Bioscience has a Debt to Equity ratio of 1.3048 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Vanta Bioscience has reported revenue growth of -44.6944487493314 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Vanta Bioscience for the current financial year is -9.19655461827351 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Vanta Bioscience is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Vanta Bioscience is Rs -6.7094 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Vanta Bioscience in Ticker for free. Also, one can get the intrinsic value of Vanta Bioscience by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Vanta Bioscience
X